

BIOPOP pioneering Preventive Healthcare Ecosystem

Our Vision

'Building a Preventive Healthcare Ecosystem'
by commercializing advanced **Non-invasive** bio-sensing technology with actionable **AI** insights.

We create a paradigm shift from reactive treatment to proactive health management.

Core Value Proposition

Non-invasive Monitoring

NIR technology for painless, continuous measurement

AI-Powered Insights

Real-time analysis with 1500-channel spectra

3 Key Strategic Pillars

Foundation

Global IP preparation

Regulatory

FDA/CE dual-track documentation

Market Launch

Commercialization

Key Milestones

2024
BIOPOP International Founded
US HQ established in Bellevue, WA

Sep ~ Dec. 2024
Technology & Product Dev.
Non-Invasive blood component analysis
Enhanced proprietary algorithms

Jun. 2025
Developed B2B Product (Kiosk)

Jan. 2026
Participated CES 2026
B2B Kiosk Launch

Jun. 2024
Established BIOPOP Korea
R&D Center in Korea, Seoul

Jan. 2025
Participated CES 2025
Biopop Global Launch
B2C Product introduction

Sep. 2025
Market expansion
Product launch in Japan
B2B Kiosk, Isetan Dep. Store

Feb. 2026
Market expansion
MOU with K-Tigers (207 Kiosk)
Signed a purchase agreement

2026 Q3 Ready



ELIXIR-K

FORM FACTOR

Stand-type Kiosk

MEASUREMENT TIME

60 seconds

TARGET BIOMARKERS

Glucose, Oxygen Saturation, Heart Rate, Body Temperature

ACCURACY TARGET

MARD < 15% (Medical Grade Target)

CONNECTIVITY

Cloud-based API, Real-time data sync (Wi-Fi)

B2B PRICE

TBD

Primary Use Cases



Corporate Wellness
Medical Clinic




Fitness / Sports Facilities



Social Welfare
Community Health

Healthcare paradigm is shifting from cure to prevention with continuous monitoring accelerating, with CAGR of 22% through 2035.

By 2035, Approximately \$300.45 Billion



Source: Precedence Research, Non-Invasive Blood Glucose Monitoring System Market Report 2035

Market Expansion

Continuous and explosive growth in the overall healthcare sector

Technological Advancement

Integration of new technologies such as AI and IoT

Non-Invasive Growth

Solving existing market pain points through innovative technology

Key Growth Drivers



Diabetes Growth

- Over 500 million diabetes patients worldwide
- Rapidly increasing demand for continuous management



Consumer Demand

- Strong consumer need for non-invasive and painless measurement methods



Digital Health

- Expansion of digital healthcare through wearables and remote monitoring

Analysis of Competitive Landscape: Big Tech vs Startups



Big Tech

Key Players

Apple Watch

Samsung Galaxy Watch

Strengths

- Strong brand power and massive R&D capital
- Established smartwatch ecosystem

Weaknesses

- FDA approval not yet obtained; launch timing uncertain
- Consumer (B2C) focused approach rather than B2B

FDA Not Approved



Invasive CGM

Key Players

Dexcom (G7)

Abbott (Libre)

Strengths

- High measurement accuracy and FDA approved
- Pre-established healthcare insurance and distribution networks

Weaknesses

- Pain and reluctance from sensor insertion (Invasive)
- Burden of continuous recurring consumable costs

High Recurring Cost



Non-invasive

Key Players

biopop

Others (Cnoga, etc)

Strengths

- Innovative bloodless/non-invasive technology (NIR, etc.)
- Suitable for prevention-oriented healthcare

Innovation Leader


Weaknesses

- Regulatory (FDA/CE) approvals in progress
- Need to secure initial market trust

Regulatory In-Progress

NIR sensors exhibit superior skin penetration depth compared to alternative sensors


Skin Permeability by Wavelength




- Penetrates into the blood vessels within the skin to measure components
- The NIR sensor is the most suitable technology for non-invasive blood component measurement

Proven the optimal wavelength for glucose measurement through extensive testing

Wavelength Analysis for Glucose Measurement



- Discovery of specific wavelengths capable of measuring variance rates based on glucose levels
- Ongoing device development optimized for the specific wavelengths that enable component measurement



Comparison of Real Blood Glucose with Our Instrument Measurements

Graph Interpretation

- Diagonal Dotted Line: Baseline whose actual and predicted values match 100%
- X-axis: Real Glucose
- Y axis: BIOPOPOP predicted blood sugar (Predicted Glucose)
- Blue dot: Actual measurement data distribution

Clarke Error Grid Interpretation


- Zone A: Clinically acceptable range of accuracy
- Zone B: Minor error or low treatment impact
- Zone C to E : Risk intervals that may affect treatment judgment

» Most measurements are distributed in Zone A

BIOPOP's non-invasive blood glucose measurement results show a high degree of agreement with actual blood glucose values,
Stable accuracy within the clinically acceptable margin of error was identified.

Test MARD : 8.64%

Actual vs Predicted Glucose Trend Analysis



Identify predictive patterns similar to actual blood sugar change flows

Graph Interpretation

- X-axis: Sample Index
- Y-axis: Glucose Value
- Solid blue line: Actual blood sugar value (Actual)
- Orange dotted line: BIOPOPOP predicted blood sugar values (Predicted)

Performance Analysis

- Reliable tracking of blood sugar rise and fall flow
- Maintain a similar pattern in sharp change sections
- Form a relatively low deviation between actual and predicted values

The results of the non-invasive blood glucose analysis of BIOPOP reliably reflect the actual blood glucose change trend, It shows its potential as a real-time health monitoring platform.

FVG offers the ideal European launchpad for clinical validation, CE Certificate acceleration, and new partnership discovery support.



WHO European Healthy Cities Network

Life Sciences Cluster

Access to clinical networks and potential partners across Europe



CE MDR Acceleration

Notified Body Access

Fast-track regulatory approval via established EU pathways



Partnership Support

Discovery & Connection

FVG helps identify manufacturing & clinical partners



EU Funding

Horizon Europe/EIT Health grant opportunities

"we are ready to support immediate engagement with comprehensive resources and dedicated support."

Virtual Technical Demo

On-demand sessions available for individual stakeholder groups to experience our UI/UX and backend data system. Includes interactive product walkthrough and live data visualization.

Joint Working Group


Establishing an online communication channel to exchange technical documentation, regulatory materials, and project planning resources for seamless collaboration.

Contact Information

Name: Sean Park
Role: CTO
Email: Sean@biopopinternational.com
Phone: +82 10 5389 5900

Name: Aaron Park
Role: Director of Strategy & Marketing
Email: aaron@biopopinternational.com
Phone: +82 10 5389 5900

CES 2025 Las Vegas, US.



CES 2026 Las Vegas, US.



ISETAN 2025 Tokyo, Japan



Diabetes Conference Seoul, Korea



Grazie